L
Louise Goodwin
Researcher at AstraZeneca
Publications - 8
Citations - 999
Louise Goodwin is an academic researcher from AstraZeneca. The author has contributed to research in topics: Cancer cell & ASK1. The author has an hindex of 8, co-authored 8 publications receiving 766 citations.
Papers
More filters
Journal ArticleDOI
Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress
Zachary T. Schug,Barrie Peck,Dylan T. Jones,Qifeng Zhang,Shaun E. Grosskurth,Israt S. Alam,Louise Goodwin,Elizabeth Smethurst,Susan M. Mason,Karen Blyth,Lynn McGarry,Daniel James,Emma Shanks,Gabriela Kalna,Rebecca E. Saunders,Ming Jiang,Michael Howell,Francois Lassailly,May Zaw Thin,Bradley Spencer-Dene,Gordon Stamp,Niels J. F. van den Broek,Gillian M. Mackay,Vinay Bulusu,Jurre J. Kamphorst,Saverio Tardito,David P. Strachan,Adrian L. Harris,Eric O. Aboagye,Susan E. Critchlow,Michael J.O. Wakelam,Almut Schulze,Eyal Gottlieb +32 more
TL;DR: A critical role for acetate consumption in the production of lipid biomass within the harsh tumor microenvironment is concluded, indicating a critical role in the growth of cancer cell growth under low-oxygen and lipid-depleted conditions.
Journal ArticleDOI
Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation.
Richard A. Ward,Claire Brassington,Alexander L. Breeze,Alessandro T. Caputo,Susan E. Critchlow,Gareth M. Davies,Louise Goodwin,Giles Hassall,Ryan Greenwood,Geoffrey A. Holdgate,Michael Mrosek,Richard A. Norman,Stuart E. Pearson,Jonathan Tart,Julie A. Tucker,Martin Vogtherr,David Whittaker,Jonathan Wingfield,Jon Winter,Kevin Hudson +19 more
TL;DR: Progress using fragment-based lead generation (FBLG), assisted by X-ray crystallography to develop small molecule LDHA inhibitors, which were identified through NMR and SPR screening and optimized into lead compounds with nanomolar binding affinities via fragment linking.
Journal ArticleDOI
Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival
Jason Grant Kettle,Husam Alwan,Michal Bista,Jason Breed,Nichola L. Davies,Kay Eckersley,Shaun M. Fillery,Kevin Michael Foote,Louise Goodwin,D.R Jones,Helena Käck,Alan Lau,Johannes Wilhelmus Maria Nissink,Jon Read,James S. Scott,Benjamin Taylor,Graeme Walker,Lisa Wissler,Marta Wylot +18 more
TL;DR: It is concluded that the role of MTH1 in carcinogenesis and utility of its inhibition is yet to be established and the difference between the responses of the highly selective inhibitors and published tool compounds suggests that the effect reported for the latter may be due to off-target cytotoxic effects.
Journal ArticleDOI
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
Lucy Riches,Antonio García Trinidad,Gareth Hughes,Gemma N Jones,A. Hughes,Andrew G. Thomason,Paul R. Gavine,Andy Cui,Stephanie Ling,Jonathan Stott,Roger Clark,Samantha Peel,Pendeep Gill,Louise Goodwin,Aaron Smith,Kurt Gordon Pike,Barlaam Bernard Christophe,Martin Pass,Mark J. O'Connor,Graeme C. M. Smith,Elaine Cadogan +20 more
TL;DR: It is demonstrated that AZD0156 impedes the repair of olaparib-induced DNA damage, resulting in elevated DNA double-strand break signaling, cell-cycle arrest, and apoptosis, as measured by phosphorylation of ATM substrates.
Journal ArticleDOI
Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome
Anne L. Ashford,Tom Dunkley,Tom Dunkley,Mark Cockerill,Mark Cockerill,Rachel Rowlinson,Lisa M. Baak,Raffaella Gallo,Kathryn Balmanno,Louise Goodwin,Richard A. Ward,Pamela A. Lochhead,Sylvie Guichard,Kevin Hudson,Simon J. Cook +14 more
TL;DR: It is demonstrated that DYRK1B also undergoes trans-autophosphorylation on serine-421 (S421) in vitro and in cells and that this site contributes to DYRk1B kinase activity, uncovering new links between two kinases involved in cell fate decisions.